Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.
Publication|Articles|November 1, 2024
- November 2024
- Volume 30
- Issue 12
Table Multiple Myeloma Trials November 2024
Author(s)Ryan Flinn, Mary Caffrey
Advertisement
TABLE. Multiple Myeloma: Enrollment of Black Patients in Trials Required for Initial FDA Approval
Articles in this issue
almost 2 years ago
To Improve Clinical Trial Equity in Multiple Myeloma, Just Askalmost 2 years ago
Collaborating for Cancer Care Equity: Community and Academic Insightsalmost 2 years ago
Elevating Value in Cancer Care With Innovations, Accessibility, Equityalmost 2 years ago
Innovating Cancer Care Through Equity and AI: Vanderbilt’s Visionalmost 2 years ago
Advancing Equitable Access to Elevate Value-Based Cancer Carealmost 2 years ago
Putting Patients First by Extending the Reach of World-Class Carealmost 2 years ago
NCCN Guidelines for MPN Reflect New Drugs, Focus on Clinical TrialsAdvertisement
Related to this article
We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Advertisement
Advertisement